Rybelsus 9 mg tablets, Rybelsus 1.5 mg tablets, Rybelsus 4 mg tablets, RO7795081, Rybelsus 7 mg tablets, RO7795081, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets, RO7795081, oral GLP-1R agonist (CT-996) Capsule, hard 0 mg / 1 EA - F10
BP45703
Phase 2 small_molecule active
Quick answer
Rybelsus 9 mg tablets, Rybelsus 1.5 mg tablets, Rybelsus 4 mg tablets, RO7795081, Rybelsus 7 mg tablets, RO7795081, Rybelsus 14 mg tablets, Rybelsus 3 mg tablets, RO7795081, oral GLP-1R agonist (CT-996) Capsule, hard 0 mg / 1 EA - F10 for Type 2 Diabetes Mellitus (T2D) is a Phase 2 program (small_molecule) at Roche Registration Limited with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Roche Registration Limited
- Indication
- Type 2 Diabetes Mellitus (T2D)
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active